FDA Approves First Treatment for Thyroid Eye Disease

by Medscape • 2020/01/22 • 0 Comments

The monoclonal antibody teprotumumab reduces proptosis and related eye problems in patients with thyroid-associated ophthalmopathy.
FDA Approvals

← Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals

Tangible Science Announces Successful 2019 and Timing for Tangible Boost Launch →